{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:39:29Z","timestamp":1775741969310,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.urolonc.2021.11.021","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T07:08:28Z","timestamp":1642316908000},"page":"164.e9-164.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-9813","authenticated-orcid":false,"given":"Andrew T.","family":"Gabrielson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus J.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-0900","authenticated-orcid":false,"given":"Julian","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-9596","authenticated-orcid":false,"given":"Ridwan","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-6593","authenticated-orcid":false,"given":"Esther J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Matoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-6509","authenticated-orcid":false,"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.11.021_bib0001","article-title":"Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: A joint US food and drug administration and bladder cancer advocacy network workshop","author":"Chang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2021.11.021_bib0002","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-15-1961","article-title":"The role of neoadjuvant trials in drug development for solid tumors","volume":"22","author":"Funt","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4 Pt 1","key":"10.1016\/j.urolonc.2021.11.021_bib0003","article-title":"Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer-does pT0 predict better survival than pTa\/Tis\/T1?","volume":"195","author":"Zargar","year":"2016","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2021.11.021_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"9373","key":"10.1016\/j.urolonc.2021.11.021_bib0005","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.021_bib0006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.021_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: A meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.021_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.021_bib0009","doi-asserted-by":"crossref","DOI":"10.1159\/000475030","article-title":"Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer","volume":"28","author":"Scattoni","year":"1995","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.urolonc.2021.11.021_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.24466","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer."},{"issue":"5","key":"10.1016\/j.urolonc.2021.11.021_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.02.011","article-title":"Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes","volume":"33","author":"Gandhi","year":"2015","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.021_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.11.021_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15434","article-title":"Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: Results from a global, multicentre collaboration","author":"Ravi","year":"2021","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.021_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013A current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2021.11.021_bib0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756287215599694","article-title":"Management of carcinoma in situ of the bladder: Best practice and recent developments","volume":"6","author":"Tang","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urolonc.2021.11.021_bib0016","doi-asserted-by":"crossref","unstructured":"Arjun Vasant Balar, Girish S. Kulkarni, Edward M. Uchio, Joost Boormans, Loic Mourey, Laurence Eliot Miles Krieger, Eric A. Singer, Dean F. Bajorin, Ashish M. Kamat, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Kijoeng Nam, Ekta Kapadia, Tara L. Frenkl, Ronald De Wit. Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG). meeting-report. https:\/\/doiorg\/101200\/JCO2019377_suppl350. 2019.","DOI":"10.1200\/JCO.2019.37.7_suppl.350"},{"issue":"30","key":"10.1016\/j.urolonc.2021.11.021_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for patients with high-grade, bacillus Calmette-Guerin-Refractory or relapsed non-muscle-invasive bladder cancer: A phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.11.021_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2013.04.120","article-title":"Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"190","author":"Sternberg","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.11.021_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2014.11.003","article-title":"The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: Inferior pathological outcomes but no effect on survival","volume":"193","author":"Parker","year":"2015","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.021_bib0020","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-018-2361-0","article-title":"Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy","volume":"37","author":"Vasdev","year":"2019","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.021_bib0021","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-019-02087-4","article-title":"Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy","volume":"51","author":"Amini","year":"2019","journal-title":"Int Urol Nephrol"},{"issue":"11","key":"10.1016\/j.urolonc.2021.11.021_bib0022","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.urolonc.2021.11.021_bib0023","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.urolonc.2021.11.021_bib0024","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: The NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.021_bib0025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921005366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921005366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:47Z","timestamp":1761042347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921005366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1078143921005366"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.021","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}